AMC Group Chairman, University of California, LA

AMC 集团董事长，加州大学洛杉矶分校

基本信息

批准号：
8426568
负责人：
RONALD T. MITSUYASU
金额：
$ 4.09万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/8426568
关键词：
AIDS Malignancy Consortium AIDS clinical trial group Accountability Acquired Immunodeficiency Syndrome Address Adolescent Africa African Area Arkansas Biological Markers Biology California Cancer Trials Support Unit Chairperson Cities Clinical Clinical Data Clinical Trials Clinical Trials Cooperative Group Clinical Trials Network Communities Country Decision Making Development Developmental Therapeutics Program Disease Eastern Cooperative Oncology Group Education and Outreach Enrollment Epidemic Evaluation Genetic Grant HIV Human Papillomavirus Immunologics Instruction International Intervention Kaposi Sarcoma Laboratories Leadership Lymphoma Malignant Neoplasms Mission Morbidity - disease rate National Cancer Institute National Institute of Allergy and Infectious Disease National Institute of Child Health and Human Development Oncology Group Pathologic Pathology Patients Pharmaceutical Preparations Pharmacology Population Prevention Process Protocols documentation Publications Research Research Infrastructure Research Personnel Research Training Resources Sampling Science Site Southwest Oncology Group Staging Strategic Planning Structure Supervision Testing Translational Research Universities Work authority cancer prevention cancer specimen resource cancer therapy data management improved mortality oncology operation protocol development standard of care statistical center tumor virology working group

项目摘要

Ttie AIDS Malignancy Consortium (AMC) was established in 1995 to evaluate clinical inten/entions for the treatment and prevention of malignancies in HIV and to investigate the biology of malignancies in the context of Clinical trials. Since then, the AMC has conducted 31 clinical trials involving 1934 patients with primarily HIV related malignancies, 991 (51%) enrolled since the beginning ofthe current grant cycle in 2006. Twelve studies are currently enrolling patients or are in late stages of protocol development. Several key scientific findings have emerged from AMC studies that have led to improvements in the treatment or management of patients and has helped establish the current standard of care in some cases. The group has more than doubled the number of its publication in the current cycle compared to its first 10 years. In addition, the AMC has initiated a process to include subjects with HIV-associated cancers in resource poor countries where the epidemic of HIV and cancer has grown substantially. The participation of many of the key clinical and laboratory researchers in AIDS malignancies in the USA has made the AMC the principal clinical trials group in the world dedicated to improving the treatment and prevention of cancers in this population. The scientific work ofthe group is focused in 4 disease-specific and one laboratory working groups; Kaposi's sarcoma, Lymphoma, Human Papillomavirus, Non-AIDS defining Cancers (NADC), and Laboratory and Translational Sciences Working Groups. In addition 3 resources committees support the work ofthe group; International, Outreach, Education and Recruitment and Laboratory (which oversees core labs in pharmacology, pathology, virology, biomarkers and developmental therapeutics). An Operations and Data Management Center (ODMC) at The EMMES Corporation, a Statistical Center at the University of Arkansas, and the Group Chair's Office at UCLA also support the AMC. Decision making authority is vested in the Group Chair and the Executive Committee (EC) with the Steering Committee providing scientific input and advice to the EC. The AMC consists of 8 core sites (including 3 combined city units) and 16 affiliated domestic sites. We are also in the process of establishing a network of international sites in resource-poor countries of Africa.

艾滋病恶性肿瘤联盟 (AMC) 成立于 1995 年，旨在评估艾滋病的临床意图/意图治疗和预防艾滋病毒恶性肿瘤并研究该背景下的恶性肿瘤生物学临床试验。此后，AMC 开展了 31 项临床试验，涉及 1934 名原发性患有原发性心脏病的患者。自 2006 年当前拨款周期开始以来，有 991 人 (51%) 参与了艾滋病毒相关恶性肿瘤。 12 研究目前正在招募患者或处于方案制定的后期阶段。几个关键科学 AMC 研究的结果导致了治疗或管理的改进患者，并在某些情况下帮助建立了当前的护理标准。该集团拥有超过与前 10 年相比，本周期的出版物数量增加了一倍。此外，AMC 已启动一项程序，将患有艾滋病毒相关癌症的受试者纳入资源贫乏国家，这些国家的艾滋病毒和癌症的流行大幅增长。许多关键的临床和专家的参与美国艾滋病恶性肿瘤实验室研究人员已将 AMC 作为主要临床试验小组在世界范围内致力于改善该人群癌症的治疗和预防。科学的该小组的工作重点是 4 个特定疾病工作组和 1 个实验室工作组；卡波西肉瘤，淋巴瘤、人乳头瘤病毒、非艾滋病定义的癌症 (NADC) 以及实验室和转化科学工作组。此外，3个资源委员会支持该小组的工作；国际的，外展、教育和招聘以及实验室（负责监督药理学、病理学、病毒学、生物标志物和发育疗法）。运营和数据管理 EMMES 公司的统计中心 (ODMC)、阿肯色大学的统计中心以及加州大学洛杉矶分校的集团主席办公室也为 AMC 提供支持。决策权属于集团主席执行委员会 (EC) 和指导委员会向委员会提供科学意见和建议欧共体。 AMC由8个核心站点（包括3个联合城市单元）和16个附属国内站点组成。我们还在非洲资源匮乏国家建立国际站点网络。